CEBP Infection and Cancer: Biology, Therapeutics, and Prevention Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hildesheim, A.
Right arrow Articles by Carrington, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hildesheim, A.
Right arrow Articles by Carrington, M.

Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 11 1035-1041, Copyright © 1998 by American Association for Cancer Research


ARTICLES

Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States

A Hildesheim, M Schiffman, DR Scott, D Marti, T Kissner, ME Sherman, AG Glass, MM Manos, AT Lorincz, RJ Kurman, J Buckland, BB Rush and M Carrington
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892-7374, USA. hildesha@epndce.nci.nih.gov

The host immune response to human papillomaviruses (HPVs) is believed to be an important determinant of progression of HPV-associated cervical neoplasia. Human leukocyte antigens (HLAs) are important in the presentation of foreign antigens to the immune system. Previous studies have suggested a possible association between HLA and cervical neoplasia, but the specific alleles found to be associated with disease have varied between studies. To further evaluate this issue, we conducted a nested case-control study within a 24,000-woman cohort study in the United States. A total of 711 women were selected for the study: 141 women diagnosed with high-grade squamous intraepithelial lesions (HSILs) of the cervix; 202 women diagnosed with low-grade SILs (LSILs); 166 women with no history of cervical neoplasia, but evidence of HPV-16 infection; and 202 women with no history of cervical abnormalities and who were HPV negative during follow-up as part of our cohort. Cervicovaginal lavage samples collected from participants were used for HPV testing by L1 consensus primer PCR and the Hybrid Capture tube test methods. DNA extracted from these same lavage samples were used for PCR-based HLA genotyping. Our results suggest a positive association between HLA B7 and HLA DQB1*0302 and disease. A negative association with disease was observed for HLA DRB1*1501-DQB1*0602 and DRB1*13. Associations were strongest when analyses were restricted to HPV-16-positive cases as follows. Compared with women who were cytologically normal and HPV negative, HLA B7 was associated with a 1.5-fold increased risk of HPV/LSIL [95% confidence interval (CI) = 0.95-2.5] and a 2.5-fold increased risk of HSIL (95% CI = 1.2-5.1). HLA DQB1*0302 was associated with a 1.5-fold increased risk of HPV/LSIL (95% CI = 0.94-2.4) and a 1.7-fold increased risk of HSIL (95% CI = 0.84-3.5). HLA DRB1*1501-DQB1*0602 was associated with a decreased risk of HSIL [relative risk (RR) = 0.21; 95% CI = 0.07-0.62]. HLA DRB1*13 was associated with a decreased risk of HPV/LSIL (RR = 0.78; 95% CI = 0.51-1.2) and HSIL (RR = 0.63; 95% CI = 0.30-1.3). Individuals who were either homozygous for DQB1*0302 or carriers of both B7 and DQB1*0302 were found to be at highest risk of disease (RR = 4.5, 95% CI = 1.5-14 for HPV/LSIL; and RR = 9.0, 95% CI = 2.4-34 for HSIL). No synergistic effect was observed for the alleles found to be associated with reduced risk of cervical neoplasia. Our findings support previous studies that have found HLA B7 and DQB1*0302 to be positively associated with cervical neoplasia and are consistent with those that have suggested that DRB1*13 is negatively associated with disease, but do not confirm previous assertions that DRB1*1501-DQB1*0602 increases the risk of cervical disease.


This article has been cited by other articles:


Home page
Cancer Res.Home page
M. M. Madeleine, L. G. Johnson, A. G. Smith, J. A. Hansen, B. B. Nisperos, S. Li, L.-P. Zhao, J. R. Daling, S. M. Schwartz, and D. A. Galloway
Comprehensive Analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 Loci and Squamous Cell Cervical Cancer Risk
Cancer Res., May 1, 2008; 68(9): 3532 - 3539.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. Butsch Kovacic, M. Martin, X. Gao, T. Fuksenko, C.-J. Chen, Y.-J. Cheng, J.-Y. Chen, R. Apple, A. Hildesheim, and M. Carrington
Variation of the Killer Cell Immunoglobulin-Like Receptors and HLA-C Genes in Nasopharyngeal Carcinoma
Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2673 - 2677.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
M Zoodsma, I M Nolte, M Schipper, E Oosterom, G van der Steege, E G E de Vries, G J te Meerman, and A G J van der Zee
Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study
J. Med. Genet., August 1, 2005; 42(8): e49 - e49.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
M. Carrington, S. Wang, M. P. Martin, X. Gao, M. Schiffman, J. Cheng, R. Herrero, A. C. Rodriguez, R. Kurman, R. Mortel, et al.
Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci
J. Exp. Med., April 4, 2005; 201(7): 1069 - 1075.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
M. Engelmark, A. Beskow, J. Magnusson, H. Erlich, and U. Gyllensten
Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer
Hum. Mol. Genet., September 1, 2004; 13(17): 1951 - 1958.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
H. K. G. Machulla, F. Steinborn, M. Tschigrjai, J. Langner, and N. G. Rainov
Meningioma: Is There an Association with Human Leukocyte Antigens?
Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1438 - 1442.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. J. Davidson, J. A. Davidson, J. C. Sterling, P. J. W. Baldwin, H. C. Kitchener, and P. L. Stern
Association between Human Leukocyte Antigen Polymorphism and Human Papillomavirus 16-positive Vulval Intraepithelial Neoplasia in British Women
Cancer Res., January 15, 2003; 63(2): 400 - 403.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. Hildesheim, R. J. Apple, C.-J. Chen, S. S. Wang, Y.-J. Cheng, W. Klitz, S. J. Mack, I-H. Chen, M.-M. Hsu, C.-S. Yang, et al.
Association of HLA Class I and II Alleles and Extended Haplotypes With Nasopharyngeal Carcinoma in Taiwan
J Natl Cancer Inst, December 4, 2002; 94(23): 1780 - 1789.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. S. Kadish, P. Timmins, Y. Wang, G. Y. F. Ho, R. D. Burk, J. Ketz, W. He, S. L. Romney, A. Johnson, R. Angeletti, et al.
Regression of Cervical Intraepithelial Neoplasia and Loss of Human Papillomavirus (HPV) Infection Is Associated with Cell-mediated Immune Responses to an HPV Type 16 E7 Peptide
Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 483 - 488.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. S. Wang, A. Hildesheim, X. Gao, M. Schiffman, R. Herrero, M. C. Bratti, M. E. Sherman, W. A. Barnes, M. D. Greenberg, L. McGowan, et al.
Human Leukocyte Antigen Class I Alleles and Cervical Neoplasia: No Heterozygote Advantage
Cancer Epidemiol. Biomarkers Prev., April 1, 2002; 11(4): 419 - 420.
[Full Text] [PDF]


Home page
BloodHome page
L. C. Harty, A. Y. Lin, A. M. Goldstein, E. S. Jaffe, M. Carrington, M. A. Tucker, and W. S. Modi
HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease
Blood, January 15, 2002; 99(2): 690 - 693.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
P. Lin, L. A. Koutsky, C. W. Critchlow, R. J. Apple, S. E. Hawes, J. P. Hughes, P. Toure, A. Dembele, and N. B. Kiviat
HLA Class II DR-DQ and Increased Risk of Cervical Cancer among Senegalese Women
Cancer Epidemiol. Biomarkers Prev., October 1, 2001; 10(10): 1037 - 1045.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
P. C. Maciag, N. F. Schlecht, P. S. A. Souza, E. L. Franco, L. L. Villa, and M. L. Petzl-Erler
Major Histocompatibility Complex Class II Polymorphisms and Risk of Cervical Cancer and Human Papillomavirus Infection in Brazilian Women
Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1183 - 1191.
[Abstract] [Full Text]


Home page
J. Virol.Home page
S. A. Leachman, R. E. Tigelaar, M. Shlyankevich, M. D. Slade, M. Irwin, E. Chang, T. C. Wu, W. Xiao, S. Pazhani, D. Zelterman, et al.
Granulocyte-Macrophage Colony-Stimulating Factor Priming plus Papillomavirus E6 DNA Vaccination: Effects on Papilloma Formation and Regression in the Cottontail Rabbit Papillomavirus-Rabbit Model
J. Virol., September 15, 2000; 74(18): 8700 - 8708.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.